Mechanisms of cancer metastasis to the bone
Tóm tắt
Từ khóa
Tài liệu tham khảo
Mundy GR . Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2:584–93.
Clark PE, Torti FM . Prostate cancer and bone metastases: medical treatment. Clin Orthop 2003, 415:S148–57.
Paget S . The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989; 8:98–101.
Boyce BF, Yoneda T, Guise TA . Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer 1999; 6:333–47.
Vander Griend DJ, Rinker-Schaeffer CW . A new look at an old problem: the survival and organ-specific growth of metastases. Sci STKE 2004; 2004:pe3.
Guise TA, Mundy GR . Cancer and bone. Endocr Rev 1998; 19:18–54.
Chirgwin JM, Guise TA . Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr 2000; 10:159–78.
Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50–6.
Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003; 3:537–49.
Deutsch A, Resnick D . Eccentric cortical metastases to the skeleton from bronchogenic carcinoma. Radiology 1980; 137:49–52.
Miric A, Banks M, Allen D, et al. Cortical metastatic lesions of the appendicular skeleton from tumors of known primary origin. J Surg Oncol 1998; 67:255–60.
Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res 1991; 51:3059–61.
Basolo F, Fiore L, Fontanini G, et al. Expression of and response to interleukin 6 (IL6) in human mammary tumors. Cancer Res 1996; 56:3118–22.
Blay JY, Schemann S, Favrot MC . Local production of interleukin 6 by renal adenocarcinoma in vivo. J Natl Cancer Inst 1994; 86:238.
Tabibzadeh SS, Poubouridis D, May LT, Sehgal PB . Interleukin-6 immunoreactivity in human tumors. Am J Pathol 1989; 135:427–33.
Thabard W, Collette M, Mellerin MP, et al. IL-6 upregulates its own receptor on some human myeloma cell lines. Cytokine 2001; 14:352–56.
de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95:2846–52.
Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD . IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990; 144:4226–30.
Ono K, Akatsu T, Murakami T, et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. J Bone Miner Res 2002; 17:774–81.
Pederson L, Winding B, Foged NT, Spelsberg TC, Oursler MJ . Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Cancer Res 1999; 59:5849–55.
Mancino AT, Klimberg VS, Yamamoto M, Manolagas SC, Abe E . Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res 2001; 100:18–24.
Sapi E . The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood) 2004; 229:1–11.
Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999; 103:197–206.
George J, Lai FM . Metastatic cervical carcinoma presenting as psoas abscess and osteoblastic and lytic bony metastases. Singapore Med J 1995; 36:224–7.
Joffe N, Antonioli DA . Osteoblastic bone metastases secondary to adenocarcinoma of the pancreas. Clin Radiol 1978; 29:41–6.
Paling MR, Pope TL . Computed tomography of isolated osteoblastic colon metastases in the bony pelvis. J Comput Tomogr 1988; 12:203–7.
Mohammad KS, Guise TA . Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop 2003; 415 Suppl:S67–74.
Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368:703–10.
Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1:944–9.
Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003; 100:10954–9.
Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56:663–8.
Chiao JW, Moonga BS, Yang YM, et al. Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption. Br J Cancer 2000; 83:360–5.
Alam AS, Gallagher A, Shankar V, et al. Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption. Endocrinology 1992; 130:3617–24.
Lassiter LK, Carducci MA . Endothelin receptor antagonists in the treatment of prostate cancer. Semin Oncol 2003; 30:678–88.
McCarthy TL, Ji C, Chen Y, et al. Runt domain factor (Runx)-dependent effects on CCAAT/ enhancer-binding protein delta expression and activity in osteoblasts. J Biol Chem 2000; 275:21746–53.
Thomas BG, Hamdy FC . Bone morphogenetic protein-6: potential mediator of osteoblastic metastases in prostate cancer. Prostate Cancer Prostatic Dis 2000; 3:283–5.
Brubaker KD, Corey E, Brown LG, Vessella RL . Bone morphogenetic protein signaling in prostate cancer cell lines. J Cell Biochem 2004; 91:151–60.
Ide H, Yoshida T, Matsumoto N, et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res 1997; 57:5022–7.
Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54:2372–7.
Rabbani SA, Desjardins J, Bell AW, et al. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173:1058–64.
Killian CS, Corral DA, Kawinski E, Constantine RI . Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993; 192:940–7.
Yi B, Williams PJ, Niewolna M, Wang Y, and Yoneda T . Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002; 62:917–23.
Oades GM, Coxon J, Colston KW . The potential role of bisphosphonates in prostate cancer. Prostate Cancer Prostatic Dis 2002; 5:264–72.
Yonou H, Ochiai A, Goya M, et al. Intraosseous growth of human prostate cancer in implanted adult human bone: relationship of prostate cancer cells to osteoclasts in osteoblastic metastatic lesions. Prostate 2004; 58:406–13.
Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82:858–64.
Lipton A, Small E, Saad F, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002; 20 Suppl 2:45–54.